Welcome to the 6th Annual Gene Therapy for Rare Disorders Europe Summit 2022

Gain European Regulatory Clarity to Progress Efficient & Robust Gene Therapies for Rare Disease

As more and more companies gear up for clinical activity and near approval decisions, the need to have an in-depth understanding of the regulatory frameworks and how these feed into clinical development and manufacturing processes is as vital as ever.

This year’s summit is dedicated to gaining European regulatory clarity to progress efficient and robust gene therapies for rare diseases. By giving voice to pioneering drug developers with success stories to share, experts in regulatory affairs, and the regulators themselves, this meeting is your comprehensive guide to unpicking the thorniest regulatory challenges.

Across three carefully curated days, this streamlined one-track summit will unite key gene therapy leaders from large pharma to ground-breaking biotech, academics to exciting service providers, all with the purpose of paving a way forward to successfully launch gene therapy products in Europe.

Download the full event guide to see the complete speaking list and content in store for 2022.

World-Class Speaking Faculty Includes:

Inês Alves

Patient Expert & Member of the Committee for Orphan Medicinal Products

EMA

Niklas Engler

Head Cell and Gene Therapy Strategy

Roche

P.J. Brooks

Acting Director, Office of Rare Diseases Research, NCATS

NIH

Stuart Beattie

Gene Therapy Global Regulatory CMC

Biogen

Violeta Stoyanova- Beninska

Chair of Committee for Orphan Medicinal Products

EMA

Other Events In The Gene Therapy Series

Proud to Partner With

thread-logo-blue
Yposkesi, an SK pharmteco company - May 2022
ProPharma_Color_tagline_2.0®_@10x